Israeli company NeuroDerm, Ltd. was awarded a $1 million grant by The Michael J. Fox Foundation for Parkinson’s Research. The grant, awarded to NeuroDerm for the second time, is intended to support the clinical development of its subcutaneously delivered drug for the treatment of Parkinson’s disease.
Related posts
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Israel, UK Ink Deal For Greater Innovation Collaboration
September 21, 2023
ALS Drug Receives Patent In Israel, Europe, Japan
September 20, 2023
Facebook comments